DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Aggarwal R, Charles-Schoeman C, Schessl J. et al
Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis („ProDERM Study“).
Medicine (Baltimore) 2021;
100: e23677
We do not assume any responsibility for the contents of the web pages of other providers.